Traws Pharma, Inc.
TRAW
$0.83
-$0.01-0.60%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 2.73M | 2.79M | 2.85M | 2.90M | 227.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.73M | 2.79M | 2.85M | 2.90M | 227.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 2.73M | 2.79M | 2.85M | 2.90M | 227.00K |
| SG&A Expenses | 7.80M | 8.52M | 9.67M | 11.40M | 11.69M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.35M | 20.67M | 18.63M | 23.17M | 25.13M |
| Operating Income | -19.62M | -17.88M | -15.79M | -20.27M | -24.90M |
| Income Before Tax | -19.43M | 9.17M | -13.31M | -17.82M | -140.05M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.43 | 9.17 | -13.31 | -17.82 | -140.05 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.43M | 9.17M | -13.31M | -17.82M | -140.05M |
| EBIT | -19.62M | -17.88M | -15.79M | -20.27M | -24.90M |
| EBITDA | -19.51M | -17.81M | -15.77M | -20.26M | -24.89M |
| EPS Basic | -1.56 | 1.14 | -5.24 | -6.39 | -19.74 |
| Normalized Basic EPS | -1.29 | 1.05 | -4.52 | -9.75 | -12.33 |
| EPS Diluted | -1.57 | 1.06 | -5.32 | -6.47 | -19.82 |
| Normalized Diluted EPS | -1.29 | 0.99 | -4.59 | -9.82 | -12.39 |
| Average Basic Shares Outstanding | 34.64M | 30.96M | 24.69M | 16.83M | 12.33M |
| Average Diluted Shares Outstanding | 34.64M | 31.21M | 24.93M | 17.08M | 12.58M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |